tradingkey.logo

Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia

ReutersApr 15, 2025 1:28 PM

- Immunitybio Inc IBRX.O:

  • IMMUNITYBIO ANNOUNCES FDA SUBMISSIONS OF SUPPLEMENTAL BLA FOR NMIBC PAPILLARY DISEASE AND FOR EXPANDED ACCESS OF ANKTIVA® TO TREAT LYMPHOPENIA

  • IMMUNITYBIO ANNOUNCES FDA SUBMISSIONS OF SUPPLEMENTAL BLA FOR NMIBC PAPILLARY DISEASE AND FOR EXPANDED ACCESS OF ANKTIVA® TO TREAT LYMPHOPENIA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles